Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2011 by King Khaled Eye Specialist Hospital
Sponsor:
Collaborators:
King Khaled Eye Specialist Hospital
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
Fowzan Alkuraya, King Khaled Eye Specialist Hospital
ClinicalTrials.gov Identifier:
NCT01482195
First received: September 28, 2011
Last updated: November 29, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2023
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)